Disabled Veteran to Ride 400+ Miles Across Iowa in Fight for Recovery and Reform
Veteran Paralyzed in Spinal Injury One Year Ago to Cycle 400+ Miles in RAGBRAI for Stem Cell Access and Veterans' Support
Just one year after a spinal cord injury left him without the use of his lower body, veteran Tanner Courtney is taking on an extraordinary challenge: cycling over 400 miles in the iconic RAGBRAI event. His mission— More Than a Ride —is both personal and powerful.
Tanner is raising funds for advanced stem cell therapy, a promising treatment showing real results around the world, yet still inaccessible in the U.S. due to outdated FDA regulations and pharmaceutical lobbying. 'I spent my life serving others,' Tanner says. 'Now I'm asking for help—for myself and the millions of Americans facing similar barriers.'
The fundraiser also supports his vision to build long-term resources for veteran and law enforcement communities. Tanner has pledged to match every dollar raised toward future nonprofit efforts personally.
Video Link: https://youtu.be/-ydyFXseK3M?feature=shared
Learn more and support his journey at: https://charity.pledgeit.org/2025-RAGBRAI-Ride-for-Recovery
Media Contact
Company Name: KT3 Fitness
Contact Person: Tanner Courtney
Email: Send Email
Phone: 5633210258
Country: United States
Website: https://www.kt3fitness.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13 hours ago
- Globe and Mail
Myasthenia Gravis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. ' Myasthenia Gravis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myasthenia Gravis Market. Some of the key takeaways from the Myasthenia Gravis Pipeline Report: Companies across the globe are diligently working toward developing novel Myasthenia Gravis treatment therapies with a considerable amount of success over the years. Myasthenia Gravis companies working in the treatment market are Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others, are developing therapies for the Myasthenia Gravis treatment Emerging Myasthenia Gravis therapies in the different phases of clinical trials are- Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others are expected to have a significant impact on the Myasthenia Gravis market in the coming years. In May 2025, The FDA approved a new therapy for generalized myasthenia gravis (gMG), a condition characterized by severe muscle weakness, rapid fatigue, and challenges with speech and swallowing. This new treatment, called nipocalimab and marketed as Imaavy, provides a long-lasting option for symptom management, benefiting approximately 100,000 people affected by gMG in the U.S. It is the first and only therapy designed to address the underlying cause of the disease in adults and adolescents aged 12 and older who possess specific antibodies associated with gMG. In April 2025, Nipocalimab-aahu is a human IgG1 monoclonal antibody designed to target the neonatal Fc receptor (FcRn) with high affinity, thereby reducing circulating IgG levels. Its approval was supported by results from the Phase 3 Vivacity-MG3 trial ( ID: NCT04951622), a randomized, double-blind, placebo-controlled study. The trial involved adult patients with generalized myasthenia gravis (gMG), classified as class II to IV by the Myasthenia Gravis Foundation of America, who had an inadequate response to standard therapies, indicated by an MG-ADL score of 6 or above. In April 2025, Promising results from the Phase 3 clinical trial (NCT05737160) assessing the safety and efficacy of Telitacicept (RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were shared during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting. In April 2025, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotech company focused on developing cell therapies for autoimmune disorders, has reported 12-month efficacy and safety results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Patients who received a single six-week treatment course of Descartes-08 showed sustained improvement in MG symptoms, which persisted through the 12-month follow-up evaluation. In March 2025, Immunovant decided not to pursue regulatory approval for its myasthenia gravis (MG) treatment, batoclimab, despite the Phase III study meeting its primary endpoint of reducing disease symptoms. Instead, the company will leverage the data to further develop its alternative therapy, IMVT-1402. The Phase III randomized trial (NCT05403541) assessed the impact of weekly or bi-monthly doses of batoclimab on acetylcholine receptor antibody-positive (AChR+) patients, using the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over a 12-week period. In December 2024, Cartesian Therapeutics revealed updated efficacy and safety data from the Phase IIb trial of its mRNA cell therapy candidate, Descartes-08, for generalized myasthenia gravis (MG). The results showed sustained responses at the 12-month mark. The double-blind, placebo-controlled, crossover trial (NCT06038474) was open-label and involved 36 heavily pre-treated, symptomatic patients. Half of the participants received a placebo, while the other half were treated with Descartes-08, both administered as six weekly outpatient infusions without prior chemotherapy preconditioning. Myasthenia Gravis Overview Myasthenia Gravis is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The name, which translates to "grave muscle weakness," reflects the primary symptom of the condition. Myasthenia Gravis occurs when the immune system produces antibodies that interfere with the communication between nerves and muscles. Get a Free Sample PDF Report to know more about Myasthenia Gravis Pipeline Therapeutic Assessment- Emerging Myasthenia Gravis Drugs Under Different Phases of Clinical Development Include: Povetacicept: Alpine Immune Science TOL 2: Toleranzia MuSK-CAART: Cabaletta Bio RLYB116: Rallybio ALXN2050: Alexion Pharmaceuticals TAK-079: Takeda Descartes-08: Cartesian Therapeutics Telitacicept: RemeGen I nebilizumab: Horizon Therapeutics Myasthenia Gravis Route of Administration Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Infusion Intradermal Intramuscular Intranasal Oral Parenteral Subcutaneous Topical Molecule Type Myasthenia Gravis Molecule Type Myasthenia Gravis Products have been categorized under various Molecule types, such as Vaccines Monoclonal Antibody Peptides Polymer Small molecule Product Type Myasthenia Gravis Pipeline Therapeutics Assessment Myasthenia Gravis Assessment by Product Type Myasthenia Gravis By Stage and Product Type Myasthenia Gravis Assessment by Route of Administration Myasthenia Gravis By Stage and Route of Administration Myasthenia Gravis Assessment by Molecule Type Myasthenia Gravis by Stage and Molecule Type DelveInsight's Myasthenia Gravis Report covers around 22+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Myasthenia Gravis product details are provided in the report. Download the Myasthenia Gravis pipeline report to learn more about the emerging Myasthenia Gravis therapies Some of the key companies in the Myasthenia Gravis Therapeutics Market include: Key companies developing therapies for Myasthenia Gravis are - CuraVac, Grifols SA, Immunovant, Mitsubishi Tanabe Pharma, Novartis, Alexion Pharmaceutical, Argenx, Astellas Pharma, UCB Pharma, Bausch Health, and others. Myasthenia Gravis Pipeline Analysis: The Myasthenia Gravis pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment. Myasthenia Gravis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Myasthenia Gravis drugs and therapies Myasthenia Gravis Pipeline Market Drivers Increasing prevalence of Myasthenis gravis, growing awareness regarding the myasthenia gravis diagnosis options, surge in geriatric population with autoimmune disease are some of the important factors that are fueling the Myasthenia Gravis Market. Myasthenia Gravis Pipeline Market Barriers However, limited reimbursement policies, high cost associated with the treatment and other factors are creating obstacles in the Myasthenia Gravis Market growth. Scope of Myasthenia Gravis Pipeline Drug Insight Coverage: Global Key Myasthenia Gravis Companies: Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others Key Myasthenia Gravis Therapies: Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers Table of Contents 1. Myasthenia Gravis Report Introduction 2. Myasthenia Gravis Executive Summary 3. Myasthenia Gravis Overview 4. Myasthenia Gravis- Analytical Perspective In-depth Commercial Assessment 5. Myasthenia Gravis Pipeline Therapeutics 6. Myasthenia Gravis Late Stage Products (Phase II/III) 7. Myasthenia Gravis Mid Stage Products (Phase II) 8. Myasthenia Gravis Early Stage Products (Phase I) 9. Myasthenia Gravis Preclinical Stage Products 10. Myasthenia Gravis Therapeutics Assessment 11. Myasthenia Gravis Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Myasthenia Gravis Key Companies 14. Myasthenia Gravis Key Products 15. Myasthenia Gravis Unmet Needs 16 . Myasthenia Gravis Market Drivers and Barriers 17. Myasthenia Gravis Future Perspectives and Conclusion 18. Myasthenia Gravis Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
15 hours ago
- Globe and Mail
Nutriband (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
Nutriband (NASDAQ: NTRB) announced it will participate in the Emerging Growth Conference on August 20, 2025. Chairman Serguei Melnik will deliver a live, interactive presentation and may open the floor for real-time questions from shareholders and the investment community. To view the full article, visit About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas 512.354.7000 Office Editor@ BioMedWire is powered by IBN
Globe and Mail
20 hours ago
- Globe and Mail
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease. The stock gained more than 1% in pre-market on Aug. 19, 2025. FDA Gives Green Signal to Wegovy for MASH On Friday, the company announced that Wegovy had been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. The treatment is to be used in combination with a reduced-calorie diet and increased physical activity. First GLP-1 Therapy Approved for MASH The approval makes Wegovy the first GLP-1 class treatment authorized for MASH, a progressive liver condition estimated to affect around 5% of U.S. adults, according to the American Liver Foundation, as quoted on CNBC. This achievement expands Wegovy's use beyond diabetes and obesity, strengthening Novo Nordisk's position in the metabolic disease market. Previous studies have also shown the drug's effectiveness in lowering the risks of heart attack, stroke and cardiovascular-related death. Results From the ESSENCE Trial The approval is based on results from the first phase of the ESSENCE trial, which revealed Wegovy's superior efficacy over placebo in improving liver fibrosis. Notably, 62.9% of participants on Wegovy achieved the resolution of steatohepatitis with no worsening of fibrosis compared to 34.3% on placebo. About 36.8% achieved improvement in liver fibrosis without worsening steatohepatitis after 72 weeks versus 22.4% on placebo. The second phase of the trial is expected to conclude in 2029. Market Impact Novo Nordisk confirmed that Wegovy would be immediately available in the United States for MASH treatment. Currently, the only other FDA-approved therapy for MASH is Madrigal Pharmaceuticals' Rezdiffra, which received clearance in 2024. This means Novo Nordisk's Wegovy should make a killing from businesses generated from MASH treatment. NVO-Heavy ETFs in Focus Against this backdrop, below we highlight a few winning exchange-traded funds (ETFs) that are heavy on Novo Nordisk. The NVO has solid exposure to ETFs like Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and VanEck Pharmaceutical ETF PPH. Boost Your Portfolio with Our Top ETF Insights Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week. Don't miss out on this valuable resource. It's free! Get it now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report VanEck Pharmaceutical ETF (PPH): ETF Research Reports Roundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports This article originally published on Zacks Investment Research (
